Knowing is half the battle: Targeting virulence factors of Group a Streptococcus for vaccine and therapeutics

Current Drug Targets

Volumn 13, Issue 3, 2012, Pages 308-322

  Thomas, Clayton L ^a   Lee, Shaun W ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Antivirulence; Group a Streptococcus; Host pathogen interactions; Therapeutics; Vaccines

Indexed keywords

AP CECT 7121; BACTERIAL VACCINE; BACTERIOCIN; CHOLERA TOXIN B SUBUNIT; CLINDAMYCIN; CYTOLYSIN; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DEOXYRIBONUCLEASE; ERYTHROMYCIN; EXOTOXIN; FBAA VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; LINEZOLID; LIPOTEICHOIC ACID; M PROTEIN; ORITAVANCIN; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN PARC; QUINOLONE; STREPTOCOCCUS GROUP A VACCINE; STREPTOKINASE; STREPTOLYSIN O; STREPTOLYSIN S; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; BACTERIOPHAGE; CELLULITIS; CLOSTRIDIUM BOTULINUM; ENTEROCOCCUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GENE MUTATION; GROUP A STREPTOCOCCAL INFECTION; HAEMOPHILUS INFLUENZAE; HUMAN; LISTERIA MONOCYTOGENES; NONHUMAN; PHARYNGITIS; PROTEOMICS; REVIEW; SALMONELLA TYPHIMURIUM; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; STREPTOCOCCUS SALIVARIUS; TOXIC SHOCK SYNDROME;

ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS PYOGENES; VIRULENCE FACTORS;

EID: 84863118766     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799424679     Document Type: Review

References (218)

1. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis 2005; 5: 685-694.
2. Steer AC, Carapetis JR, Nolan TM, Shann F. Systematic review of rheumatic heart disease prevalence in children in developing countries: the role of environmental factors. J Paediatr Child Health 2002; 38: 229-234.
3. Bisno AL. Acute pharyngitis. N Engl J Med 2001; 344: 205-211.
4. Komaroff AL, Pass TM, Aronson MD, et al. The prediction of streptococcal pharyngitis in adults. J Gen Intern Med 1986; 1: 1-7.
5. Carapetis JR. Current issues in managing group A streptococcal infections. Adv Exp Med Biol 2004; 549: 185-190.
6. Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. Lancet Infect Dis 2003; 3: 191-200.
7. Aziz RK, Kotb M. Rise and persistence of global M1T1 clone of Streptococcus pyogenes. Emerg Infect Dis 2008; 14: 1511-1517.
8. Bisno AL, Rubin FA, Cleary PP, Dale JB. Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop. Clin Infect Dis 2005; 41: 1150-1156.
9. Reid SD, Hoe NP, Smoot LM, Musser JM. Group A Streptococcus: allelic variation, population genetics, and host-pathogen interactions. J Clin Invest 2001; 107: 393-399.
10. Martin JM, Green M, Barbadora KA, Wald ER. Erythromycinresistant group A streptococci in schoolchildren in Pittsburgh. N Engl J Med 2002; 346: 1200-1206.
11. Yan SS, Fox ML, Holland SM, et al. Resistance to multiple fluoroquinolones in a clinical isolate of Streptococcus pyogenes: identification of gyrA and parC and specification of point mutations associated with resistance. Antimicrob Agents Chemother 2000; 44: 3196-3198.
12. Richter SS, Diekema DJ, Heilmann KP, et al. Fluoroquinolone resistance in Streptococcus pyogenes. Clin Infect Dis 2003; 36: 380-383.
13. de Almeida Torres RS, de Almeida Torres RP, Smeesters PR, et al. Group A Streptococcus Antibiotic Resistance in Southern Brazil: A 17-Year Surveillance Study. Microb Drug Resist 2011;
14. Musser JM, Shelburne SA, 3rd. A decade of molecular pathogenomic analysis of group A Streptococcus. J Clin Invest 2009; 119: 2455-2463.
15. Courtney HS, Hasty DL, Dale JB. Molecular mechanisms of adhesion, colonization, and invasion of group A streptococci. Ann Med 2002; 34: 77-87.
16. Fischetti VA. Streptococcal M protein: molecular design and biological behavior. Clin Microbiol Rev 1989; 2: 285-314.
17. Fischetti VA. Streptococcal M protein. Sci Am 1991; 264: 58-65.
18. Bisno AL. Alternate complement pathway activation by group A streptococci: role of M-protein. Infect Immun 1979; 26: 1172-1176.
19. Horstmann RD, Sievertsen HJ, Knobloch J, Fischetti VA. Antiphagocytic activity of streptococcal M protein: selective binding of complement control protein factor H. Proc Natl Acad Sci USA 1988; 85: 1657-1661.
20. Hanski E, Caparon M. Protein F, a fibronectin-binding protein, is an adhesin of the group A streptococcus Streptococcus pyogenes. Proc Natl Acad Sci USA 1992; 89: 6172-1676.
21. Hanski E, Horwitz PA, Caparon MG. Expression of protein F, the fibronectin-binding protein of Streptococcus pyogenes JRS4, in heterologous streptococcal and enterococcal strains promotes their adherence to respiratory epithelial cells. Infect Immun 1992; 60: 5119-5125.
22. Guzman CA, Talay SR, Molinari G, Medina E, Chhatwal GS. Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. J Infect Dis 1999; 179: 901-906.
23. Talay SR, Zock A, Rohde M, et al. Co-operative binding of human fibronectin to Sfbl protein triggers streptococcal invasion into respiratory epithelial cells. Cell Microbiol 2000; 2: 521-535.
24. Schulze K, Medina E, Chhatwal GS, Guzman CA. Stimulation of long-lasting protection against Streptococcus pyogenes after intranasal vaccination with non adjuvanted fibronectin-binding domain of the SfbI protein. Vaccine 2003; 21: 1958-1964.
25. McArthur J, Medina E, Mueller A, et al. Intranasal vaccination with streptococcal fibronectin binding protein Sfb1 fails to prevent growth and dissemination of Streptococcus pyogenes in a murine skin infection model. Infect Immun 2004; 72: 7342-7345.
26. Terao Y, Okamoto S, Kataoka K, Hamada S, Kawabata S. Protective immunity against Streptococcus pyogenes challenge in mice after immunization with fibronectin-binding protein. J Infect Dis 2005; 192: 2081-2091.
27. Chabria M, Hertig S, Smith ML, Vogel V. Stretching fibronectin fibres disrupts binding of bacterial adhesins by physically destroying an epitope. Nat Commun 2010; 1: 135.
28. Beachey EH, Ofek I. Epithelial cell binding of group A streptococci by lipoteichoic acid on fimbriae denuded of M protein. J Exp Med 1976; 143: 759-771.
29. Simpson WA, Beachey EH. Adherence of group A streptococci to fibronectin on oral epithelial cells. Infect Immun 1983; 39: 275-279.
30. Dale JB, Baird RW, Courtney HS, Hasty DL, Bronze MS. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J Infect Dis 1994; 169: 319-323.
31. Sela S, Marouni MJ, Perry R, Barzilai A. Effect of lipoteichoic acid on the uptake of Streptococcus pyogenes by HEp-2 cells. FEMS Microbiol Lett 2000; 193: 187-193.
32. Yokoyama Y, Harabuchi Y. Intranasal immunization with lipoteichoic acid and cholera toxin evokes specific pharyngeal IgA and systemic IgG responses and inhibits streptococcal adherence to pharyngeal epithelial cells in mice. Int J Pediatr Otorhinolaryngol 2002; 63: 235-241.
33. Smeesters PR, McMillan DJ, Sriprakash KS. The streptococcal M protein: a highly versatile molecule. Trends Microbiol 2010; 18: 275-282.
34. Berggard K, Johnsson E, Morfeldt E, et al. Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes. Mol Microbiol 2001; 42: 539-551.
35. Perez-Caballero D, Alberti S, Vivanco F, Sanchez-Corral P, Rodriguez de Cordoba S. Assessment of the interaction of human complement regulatory proteins with group A Streptococcus. Identification of a high-affinity group A Streptococcus binding site in FHL-1. Eur J Immunol 2000; 30: 1243-1253.
36. Fischetti VA, Horstmann RD, Pancholi V. Location of the complement factor H binding site on streptococcal M6 protein. Infect Immun 1995; 63: 149-153.
37. Perez-Caballero D, Garcia-Laorden I, Cortes G, et al. Interaction between complement regulators and Streptococcus pyogenes: binding of C4b-binding protein and factor H/factor H-like protein 1 to M18 strains involves two different cell surface molecules. J Immunol 2004; 173: 6899-6904.
38. Carlsson F, Sandin C, Lindahl G. Human fibrinogen bound to Streptococcus pyogenes M protein inhibits complement deposition via the classical pathway. Mol Microbiol 2005; 56: 28-39.
39. Courtney HS, Ofek I, Penfound T, et al. Relationship between expression of the family of M proteins and lipoteichoic acid to hydrophobicity and biofilm formation in Streptococcus pyogenes. PLoS One 2009; 4: e4166.
40. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev 2000; 13: 470-511.
41. Lancefield RC. A Serological Differentiation of Human and Other Groups of Hemolytic Streptococci. J Exp Med 1933; 57: 571-595.
42. Dale JB. Current status of group A streptococcal vaccine development. Adv Exp Med Biol 2008; 609: 53-63.
43. Steer AC, Batzloff MR, Mulholland K, Carapetis JR. Group A streptococcal vaccines: facts versus fantasy. Curr Opin Infect Dis 2009; 22: 544-552.
44. Dale JB, Chiang EC. Intranasal immunization with recombinant group A streptococcal M protein fragment fused to the B subunit of Escherichia coli labile toxin protects mice against systemic challenge infections. J Infect Dis 1995; 171: 1038-1041.
45. McNeil SA, Halperin SA, Langley JM, et al. Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. Clin Infect Dis 2005; 41: 1114-1122.
46. Kaplan EL, Wotton JT, Johnson DR. Dynamic epidemiology of group A streptococcal serotypes associated with pharyngitis. Lancet 2001; 358: 1334-1337.
47. Smeesters PR, Vergison A, Campos D, et al. Differences between Belgian and Brazilian group A Streptococcus epidemiologic landscape. PLoS One 2006; 1: e10.
48. Steer AC, Magor G, Jenney AW, et al. Emm and C-repeat region molecular typing of beta-hemolytic Streptococci in a tropical country: implications for vaccine development. J Clin Microbiol 2009; 47: 2502-2509.
49. Batzloff MR, Hayman WA, Davies MR, et al. Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. J Infect Dis 2003; 187: 1598-1608.
50. Guilherme L, Postol E, Freschi de Barros S, et al. A vaccine against S. pyogenes: design and experimental immune response. Methods 2009; 49: 316-321.
51. Pandey M, Sekuloski S, Batzloff MR. Novel strategies for controlling Streptococcus pyogenes infection and associated diseases: from potential peptide vaccines to antibody immunotherapy. Immunol Cell Biol 2009; 87: 391-399.
52. Olive C, Schulze K, Sun HK, et al. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation. Vaccine 2007; 25: 1789-1797.
53. Crater DL, van de Rijn I. Hyaluronic acid synthesis operon (has) expression in group A streptococci. J Biol Chem 1995; 270: 18452-18458.
54. Alberti S, Ashbaugh CD, Wessels MR. Structure of the has operon promoter and regulation of hyaluronic acid capsule expression in group A Streptococcus. Mol Microbiol 1998; 28: 343-353.
55. Stollerman GH, Dale JB. The importance of the group a streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin Infect Dis 2008; 46: 1038-1045.
56. Wessels MR, Moses AE, Goldberg JB, DiCesare TJ. Hyaluronic acid capsule is a virulence factor for mucoid group A streptococci. Proc Natl Acad Sci USA 1991; 88: 8317-8321.
57. Dale JB, Washburn RG, Marques MB, Wessels MR. Hyaluronate capsule and surface M protein in resistance to opsonization of group A streptococci. Infect Immun 1996; 64: 1495-1501.
58. Starr CR, Engleberg NC. Role of hyaluronidase in subcutaneous spread and growth of group A streptococcus. Infect Immun 2006; 74: 40-48.
59. Cole JN, Pence MA, von Kockritz-Blickwede M, et al. M Protein and Hyaluronic Acid Capsule Are Essential for In Vivo Selection of covRS Mutations Characteristic of Invasive Serotype M1T1 Group A Streptococcus. MBio 2010; 1.
60. Okamoto S, Kawabata S, Terao Y, et al. The Streptococcus pyogenes capsule is required for adhesion of bacteria to virusinfected alveolar epithelial cells and lethal bacterial-viral superinfection. Infect Immun 2004; 72: 6068-6075.
61. Fillit HM, McCarty M, Blake M. Induction of antibodies to hyaluronic acid by immunization of rabbits with encapsulated streptococci. J Exp Med 1986; 164: 762-776.
62. Fillit HM, Blake M, MacDonald C, McCarty M. Immunogenicity of liposome-bound hyaluronate in mice. At least two different antigenic sites on hyaluronate are identified by mouse monoclonal antibodies. J Exp Med 1988; 168: 971-982.
63. Gryllos I, Tran-Winkler HJ, Cheng MF, et al. Induction of group A Streptococcus virulence by a human antimicrobial peptide. Proc Natl Acad Sci USA 2008; 105: 16755-16760.
64. Telford JL, Barocchi MA, Margarit I, Rappuoli R, Grandi G. Pili in gram-positive pathogens. Nat Rev Microbiol 2006; 4: 509-519.
65. Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA 2006; 103: 2857-2862.
66. Maisey HC, Hensler M, Nizet V, Doran KS. Group B streptococcal pilus proteins contribute to adherence to and invasion of brain microvascular endothelial cells. J Bacteriol 2007; 189: 1464-1467.
67. Maisey HC, Quach D, Hensler ME, et al. A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence. FASEB J 2008; 22: 1715-1724.
68. Mora M, Bensi G, Capo S, et al. Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens. Proc Natl Acad Sci USA 2005; 102: 15641-15646.
69. Manetti AG, Zingaretti C, Falugi F, et al. Streptococcus pyogenes pili promote pharyngeal cell adhesion and biofilm formation. Mol Microbiol 2007; 64: 968-983.
70. Edwards AM, Manetti AG, Falugi F, et al. Scavenger receptor gp340 aggregates group A streptococci by binding pili. Mol Microbiol 2008; 68: 1378-1394.
71. Abbot EL, Smith WD, Siou GP, et al. Pili mediate specific adhesion of Streptococcus pyogenes to human tonsil and skin. Cell Microbiol 2007; 9: 1822-1833.
72. Crotty Alexander LE, Maisey HC, Timmer AM, et al. M1T1 group A streptococcal pili promote epithelial colonization but diminish systemic virulence through neutrophil extracellular entrapment. J Mol Med 2010; 88: 371-381.
73. Soriani M, Telford JL. Relevance of pili in pathogenic streptococci pathogenesis and vaccine development. Future Microbiol 2010; 5: 735-747.
74. Margarit I, Rinaudo CD, Galeotti CL, et al. Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. J Infect Dis 2009; 199: 108-115.
75. Falugi F, Zingaretti C, Pinto V, et al. Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. J Infect Dis 2008; 198: 1834-1841.
76. Nizet V. Streptococcal beta-hemolysins: genetics and role in disease pathogenesis. Trends Microbiol 2002; 10: 575-580.
77. Hakansson A, Bentley CC, Shakhnovic EA, Wessels MR. Cytolysin-dependent evasion of lysosomal killing. Proc Natl Acad Sci USA 2005; 102: 5192-5197.
78. Logsdon LK, Hakansson AP, Cortes G, Wessels MR. Streptolysin o inhibits clathrin-dependent internalization of group a streptococcus. MBio 2011; 2.
79. Dietrich G, Hess J, Gentschev I, et al. From evil to good: a cytolysin in vaccine development. Trends Microbiol 2001; 9: 23-28.
80. Ginsburg I, Harris TN, Grossowicz N. Oxygen-Stable Hemolysins of Group a Streptococci. I. The Role of Various Agents in the Production of the Hemolysins. J Exp Med 1963; 118: 905-17.
81. Koyama J. Biochemical Studies on Streptolysin S'. Ii. Properties of a Polypeptide Component and Its Role in the Toxin Activity. J Biochem 1963; 54: 146-151.
82. Koyama J. Biochemical Studies on Streptolysin S'. Iv. Properties of the Oligoribonucleotide Portion. J Biochem 1964; 56: 355-360.
83. Bernheimer AW. Physical behavior of streptolysin S. J Bacteriol 1967; 93: 2024-2025.
84. Bernheimer AW, Rudy B. Interactions between membranes and cytolytic peptides. Biochim Biophys Acta 1986; 864: 123-141.
85. Bernheimer AW. Disruption of wall-less bacteria by streptococcal and staphylococcal toxins. J Bacteriol 1966; 91: 1677-1680.
86. Wannamaker LW. Streptococcal toxins. Rev Infect Dis 1983; 5 Suppl 4: S723-S732.
87. Ginsburg I. Mechanisms of cell and tissue injury induced by group A streptococci: relation to poststreptococcal sequelae. J Infect Dis 1972; 126: 294-340.
88. Ginsburg I. Is streptolysin S of group A streptococci a virulence factor? APMIS 1999; 107: 1051-1059.
89. Humar D, Datta V, Bast DJ, et al. Streptolysin S and necrotizing infections produced by group G streptococcus. Lancet 2002; 359: 124-129.
90. Lin A, Loughman JA, Zinselmeyer BH, Miller MJ, Caparon MG. Streptolysin S inhibits neutrophil recruitment during the early stages of Streptococcus pyogenes infection. Infect Immun 2009; 77: 5190-5201.
91. Miyoshi-Akiyama T, Takamatsu D, Koyanagi M, et al. Cytocidal effect of Streptococcus pyogenes on mouse neutrophils in vivo and the critical role of streptolysin S. J Infect Dis 2005; 192: 107-116.
92. Sumitomo T, Nakata M, Higashino M, et al. Streptolysin S contributes to group A streptococcal translocation across an epithelial barrier. J Biol Chem 2011; 286: 2750-2761.
93. Nizet V, Beall B, Bast DJ, et al. Genetic locus for streptolysin S production by group A streptococcus. Infect Immun 2000; 68: 4245-4254.
94. Walsh CT, Nolan EM. Morphing peptide backbones into heterocycles. Proc Natl Acad Sci USA 2008; 105: 5655-5656.
95. Belshaw PJ, Roy RS, Kelleher NL, Walsh CT. Kinetics and regioselectivity of peptide-to-heterocycle conversions by microcin B17 synthetase. Chem Biol 1998; 5: 373-384.
96. Heddle JG, Blance SJ, Zamble DB, et al. The antibiotic microcin B17 is a DNA gyrase poison: characterisation of the mode of inhibition. J Mol Biol 2001; 307: 1223-1234.
97. Kelleher NL, Hendrickson CL, Walsh CT. Posttranslational heterocyclization of cysteine and serine residues in the antibiotic microcin B17: distributivity and directionality. Biochemistry 1999; 38: 15623-15630.
98. Li YM, Milne JC, Madison LL, Kolter R, Walsh CT. From peptide precursors to oxazole and thiazole-containing peptide antibiotics: microcin B17 synthase. Science 1996; 274: 1188-1193.
99. Madison LL, Vivas EI, Li YM, Walsh CT, Kolter R. The leader peptide is essential for the post-translational modification of the DNA-gyrase inhibitor microcin B17. Mol Microbiol 1997; 23: 161-168.
100. Milne JC, Eliot AC, Kelleher NL, Walsh CT. ATP/GTP hydrolysis is required for oxazole and thiazole biosynthesis in the peptide antibiotic microcin B17. Biochemistry 1998; 37: 13250-13261.
101. Milne JC, Roy RS, Eliot AC, et al. Cofactor requirements and reconstitution of microcin B17 synthetase: a multienzyme complex that catalyzes the formation of oxazoles and thiazoles in the antibiotic microcin B17. Biochemistry 1999; 38: 4768-4781.
102. Nolan EM, Walsh CT. How nature morphs peptide scaffolds into antibiotics. Chembiochem 2009; 10: 34-53.
103. Regni CA, Roush RF, Miller DJ, et al. How the MccB bacterial ancestor of ubiquitin E1 initiates biosynthesis of the microcin C7 antibiotic. EMBO J 2009; 28: 1953-1964.
104. Roy RS, Allen O, Walsh CT. Expressed protein ligation to probe regiospecificity of heterocyclization in the peptide antibiotic microcin B17. Chem Biol 1999; 6: 789-799.
105. Roy RS, Kim S, Baleja JD, Walsh CT. Role of the microcin B17 propeptide in substrate recognition: solution structure and mutational analysis of McbA1-26. Chem Biol 1998; 5: 217-228.
106. Sinha Roy R, Belshaw PJ, Walsh CT. Mutational analysis of posttranslational heterocycle biosynthesis in the gyrase inhibitor microcin B17: distance dependence from propeptide and tolerance for substitution in a GSCG cyclizable sequence. Biochemistry 1998; 37: 4125-4136.
107. Sinha Roy R, Kelleher NL, Milne JC, Walsh CT. In vivo processing and antibiotic activity of microcin B17 analogs with varying ring content and altered bisheterocyclic sites. Chem Biol 1999; 6: 305-318.
108. Zamble DB, McClure CP, Penner-Hahn JE, Walsh CT. The McbB component of microcin B17 synthetase is a zinc metalloprotein. Biochemistry 2000; 39: 16190-16199.
109. Zamble DB, Miller DA, Heddle JG, et al. In vitro characterization of DNA gyrase inhibition by microcin B17 analogs with altered bisheterocyclic sites. Proc Natl Acad Sci USA 2001; 98: 7712-77127.
110. Lee SW, Mitchell DA, Markley AL, et al. Discovery of a widely distributed toxin biosynthetic gene cluster. Proc Natl Acad Sci USA 2008; 105: 5879-5884.
111. Schmidt EW, Nelson JT, Rasko DA, et al. Patellamide A and C biosynthesis by a microcin-like pathway in Prochloron didemni, the cyanobacterial symbiont of Lissoclinum patella. Proc Natl Acad Sci USA 2005; 102: 7315-7320.
112. Sudek S, Haygood MG, Youssef DT, Schmidt EW. Structure of trichamide, a cyclic peptide from the bloom-forming cyanobacterium Trichodesmium erythraeum, predicted from the genome sequence. Appl Environ Microbiol 2006; 72: 4382-4387.
113. Igarashi Y, Kan Y, Fujii K, et al. Goadsporin, a chemical substance which promotes secondary metabolism and Morphogenesis in streptomycetes. II. Structure determination. J Antibiot (Tokyo) 2001; 54: 1045-1053.
114. Cotter PD, Draper LA, Lawton EM, et al. Listeriolysin S, a novel peptide haemolysin associated with a subset of lineage I Listeria monocytogenes. PLoS Pathog 2008; 4: e1000144.
115. Mitchell DA, Lee SW, Pence MA, et al. Structural and functional dissection of the heterocyclic peptide cytotoxin streptolysin S. J Biol Chem 2009; 284: 13004-13012.
116. Gonzalez DJ, Lee SW, Hensler ME, et al. Clostridiolysin S, a posttranslationally modified biotoxin from Clostridium botulinum. J Biol Chem 2010; 285: 28220-28228.
117. Scholz R, Molohon KJ, Nachtigall J, et al. Plantazolicin, a novel microcin B17/streptolysin S-like natural product from Bacillus amyloliquefaciens FZB42. J Bacteriol 2011; 193: 215-224.
118. Yorgey P, Lee J, Kordel J, et al. Posttranslational modifications in microcin B17 define an additional class of DNA gyrase inhibitor. Proc Natl Acad Sci USA 1994; 91: 4519-4523.
119. Dale JB, Chiang EY, Hasty DL, Courtney HS. Antibodies against a synthetic peptide of SagA neutralize the cytolytic activity of streptolysin S from group A streptococci. Infect Immun 2002; 70: 2166-2170.
120. Papageorgiou AC, Acharya KR. Microbial superantigens: from structure to function. Trends Microbiol 2000; 8: 369-375.
121. Bohach GA, Fast DJ, Nelson RD, Schlievert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990; 17: 251-272.
122. Hauser AR, Stevens DL, Kaplan EL, Schlievert PM. Molecular analysis of pyrogenic exotoxins from Streptococcus pyogenes isolates associated with toxic shock-like syndrome. J Clin Microbiol 1991; 29: 1562-1567.
123. Buonpane RA, Churchill HR, Moza B, et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 2007; 13: 725-729.
124. Wang N, Mattis DM, Sundberg EJ, Schlievert PM, Kranz DM. A single, engineered protein therapeutic agent neutralizes exotoxins from both Staphylococcus aureus and Streptococcus pyogenes. Clin Vaccine Immunol 2010; 17: 1781-1789.
125. Leggiadro RJ, Bugnitz MC, Peck BA, et al. Group A streptococcal bacteremia in a mid-south children's hospital. South Med J 1993; 86: 615-618.
126. Imohl M, Reinert RR, Ocklenburg C, van der Linden M. Epidemiology of invasive Streptococcus pyogenes disease in Germany during 2003-2007. FEMS Immunol Med Microbiol 2010; 58: 389-396.
127. McCormick JK, Tripp TJ, Olmsted SB, et al. Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome. J Immunol 2000; 165: 2306-2312.
128. Larkin EA, Stiles BG, Ulrich RG. Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One 2010; 5: e13253.
129. Hytonen J, Haataja S, Gerlach D, Podbielski A, Finne J. The SpeB virulence factor of Streptococcus pyogenes, a multifunctional secreted and cell surface molecule with strepadhesin, lamininbinding and cysteine protease activity. Mol Microbiol 2001; 39: 512-519.
130. Shanley TP, Schrier D, Kapur V, et al. Streptococcal cysteine protease augments lung injury induced by products of group A streptococci. Infect Immun 1996; 64: 870-877.
131. Dale JB, Cleary PP, Fischetti VA, et al. Group A and group B streptococcal vaccine development. A round table presentation. Adv Exp Med Biol 1997; 418: 863-868.
132. Saouda M, Wu W, Conran P, Boyle MD. Streptococcal pyrogenic exotoxin B enhances tissue damage initiated by other Streptococcus pyogenes products. J Infect Dis 2001; 184: 723-731.
133. Kapur V, Maffei JT, Greer RS, et al. Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. Microb Pathog 1994; 16: 443-450.
134. Roggiani M, Stoehr JA, Olmsted SB, et al. Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome. Infect Immun 2000; 68: 5011-5017.
135. Ulrich RG. Vaccine based on a ubiquitous cysteinyl protease and streptococcal pyrogenic exotoxin A protects against Streptococcus pyogenes sepsis and toxic shock. J Immune Based Ther Vaccines 2008; 6: 8.
136. Nordstrand A, McShan WM, Ferretti JJ, Holm SE, Norgren M. Allele substitution of the streptokinase gene reduces the nephritogenic capacity of group A streptococcal strain NZ131. Infect Immun 2000; 68: 1019-1025.
137. Takada Y, Takada A. The mechanisms of the activation of plasminogen by streptokinase and urokinase. Adv Exp Med Biol 1990; 281: 223-234.
138. Chibber BA, Morris JP, Castellino FJ. Effects of human fibrinogen and its cleavage products on activation of human plasminogen by streptokinase. Biochemistry 1985; 24: 3429-3434.
139. Cole JN, McArthur JD, McKay FC, et al. Trigger for group A streptococcal M1T1 invasive disease. FASEB J 2006; 20: 1745-1747.
140. Sun H, Ringdahl U, Homeister JW, et al. Plasminogen is a critical host pathogenicity factor for group A streptococcal infection. Science 2004; 305: 1283-1286.
141. Cleary PP, Prahbu U, Dale JB, Wexler DE, Handley J. Streptococcal C5a peptidase is a highly specific endopeptidase. Infect Immun 1992; 60: 5219-5223.
142. Wexler DE, Chenoweth DE, Cleary PP. Mechanism of action of the group A streptococcal C5a inactivator. Proc Natl Acad Sci USA 1985; 82: 8144-8148.
143. Ji Y, McLandsborough L, Kondagunta A, Cleary PP. C5a peptidase alters clearance and trafficking of group A streptococci by infected mice. Infect Immun 1996; 64: 503-510.
144. O'Connor SP, Darip D, Fraley K, et al. The human antibody response to streptococcal C5a peptidase. J Infect Dis 1991; 163: 109-116.
145. Ji Y, Carlson B, Kondagunta A, Cleary PP. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus. Infect Immun 1997; 65: 2080-2087.
146. Cheng Q, Carlson B, Pillai S, et al. Antibody against surface-bound C5a peptidase is opsonic and initiates macrophage killing of group B streptococci. Infect Immun 2001; 69: 2302-2308.
147. Cleary PP, Matsuka YV, Huynh T, Lam H, Olmsted SB. Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. Vaccine 2004; 22: 4332-4341.
148. Park HS, Cleary PP. Active and passive intranasal immunizations with streptococcal surface protein C5a peptidase prevent infection of murine nasal mucosa-associated lymphoid tissue, a functional homologue of human tonsils. Infect Immun 2005; 73: 7878-7886.
149. Shet A, Kaplan E, Johnson D, Cleary PP. Human immunogenicity studies on group A streptococcal C5a peptidase (SCPA) as a potential vaccine against group A streptococcal infections. Indian J Med Res 2004; 119 Suppl: 95-98.
150. Shet A, Kaplan EL, Johnson DR, Cleary PP. Immune response to group A streptococcal C5a peptidase in children: implications for vaccine development. J Infect Dis 2003; 188: 809-817.
151. Allegretti M, Moriconi A, Beccari AR, et al. Targeting C5a: recent advances in drug discovery. Curr Med Chem 2005; 12: 217-236.
152. Wannamaker LW. The differentiation of three distinct desoxyrlbonucleases of group A Streptococci. J Exp Med 1958; 107: 797-812.
153. Wannamaker LW, Yasmineh W. Streptococcal nucleases. I. Further studies on the A, B, and C enzymes. J Exp Med 1967; 126: 475-496.
154. Wannamaker LW, Hayes B, Yasmineh W. Streptococcal nucleases. II. Characterization of DNAse D. J Exp Med 1967; 126: 497-508.
155. Miyakawa Y, Yamada T, Shitara M, Fukazawa Y. Electrophoretic patterns of extracellular deoxyribonuclease (DNase) and their correlation with T-type in group A streptococci. Microbiol Immunol 1985; 29: 195-204.
156. Sumby P, Barbian KD, Gardner DJ, et al. Extracellular deoxyribonuclease made by group A Streptococcus assists pathogenesis by enhancing evasion of the innate immune response. Proc Natl Acad Sci USA 2005; 102: 1679-1684.
157. Buchanan JT, Simpson AJ, Aziz RK, et al. DNase expression allows the pathogen group A Streptococcus to escape killing in neutrophil extracellular traps. Curr Biol 2006; 16: 396-400.
158. Beiter K, Wartha F, Albiger B, et al. An endonuclease allows Streptococcus pneumoniae to escape from neutrophil extracellular traps. Curr Biol 2006; 16: 401-407.
159. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science 2004; 303: 1532-1535.
160. Brinkmann V, Zychlinsky A. Beneficial suicide: why neutrophils die to make NETs. Nat Rev Microbiol 2007; 5: 577-582.
161. Hasegawa T, Minami M, Okamoto A, et al. Characterization of a virulence-associated and cell-wall-located DNase of Streptococcus pyogenes. Microbiology 2010; 156: 184-190.
162. Chang A, Khemlani A, Kang H, Proft T. Functional analysis of Streptococcus pyogenes nuclease A (SpnA), a novel group A streptococcal virulence factor. Mol Microbiol 2011; 79: 1629-1642.
163. Walker MJ, Hollands A, Sanderson-Smith ML, et al. DNase Sda1 provides selection pressure for a switch to invasive group A streptococcal infection. Nat Med 2007; 13: 981-985.
164. Sumby P, Whitney AR, Graviss EA, DeLeo FR, Musser JM. Genome-wide analysis of group a streptococci reveals a mutation that modulates global phenotype and disease specificity. PLoS Pathog 2006; 2: e5.
165. Akesson P, Sjoholm AG, Bjorck L. Protein SIC, a novel extracellular protein of Streptococcus pyogenes interfering with complement function. J Biol Chem 1996; 271: 1081-1088.
166. Fernie-King BA, Seilly DJ, Willers C, et al. Streptococcal inhibitor of complement (SIC) inhibits the membrane attack complex by preventing uptake of C567 onto cell membranes. Immunology 2001; 103: 390-398.
167. Frick IM, Akesson P, Rasmussen M, Schmidtchen A, Bjorck L. SIC, a secreted protein of Streptococcus pyogenes that inactivates antibacterial peptides. J Biol Chem 2003; 278: 16561-16566.
168. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte proteinase inhibitor and lysozyme. Infect Immun 2002; 70: 4908-4916.
169. Frick IM, Shannon O, Akesson P, et al. Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by Streptococcus pyogenes. J Biol Chem 2011; 286: 1331-1340.
170. Akesson P, Herwald H, Rasmussen M, et al. Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. Microbiology 2010; 156: 3660-3668.
171. Colman RW, Schmaier AH. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 1997; 90: 3819-3843.
172. Ben Nasr AB, Herwald H, Muller-Esterl W, Bjorck L. Human kininogens interact with M protein, a bacterial surface protein and virulence determinant. Biochem J 1995; 305 (Pt 1): 173-180.
173. Pence MA, Rooijakkers SH, Cogen AL, et al. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. J Innate Immun 2010; 2: 587-595.
174. Pichichero ME. Group A streptococcal tonsillopharyngitis: costeffective diagnosis and treatment. Ann Emerg Med 1995; 25: 390-403.
175. Dixon JM. Group A Streptococcus resistant to erythromycin and lincomycin. Can Med Assoc J 1968; 99: 1093-1094.
176. Sanders E, Foster MT, Scott D. Group A beta-hemolytic streptococci resistant to erythromycin and lincomycin. N Engl J Med 1968; 278: 538-540.
177. Freeman AF, Shulman ST. Macrolide resistance in group A Streptococcus. Pediatr Infect Dis J 2002; 21: 1158-1160.
178. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance. N Engl J Med 1997; 337: 441-446.
179. Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group a streptococci in Ontario, Canada, in 2001. Antimicrob Agents Chemother 2003; 47: 2370-2372.
180. Palavecino EL, Riedel I, Berrios X, et al. Prevalence and mechanisms of macrolide resistance in Streptococcus pyogenes in Santiago, Chile. Antimicrob Agents Chemother 2001; 45: 339-341.
181. Orscheln RC, Johnson DR, Olson SM, et al. Intrinsic reduced susceptibility of serotype 6 Streptococcus pyogenes to fluoroquinolone antibiotics. J Infect Dis 2005; 191: 1272-1279.
182. Poyart C, Pierre C, Quesne G, et al. Emergence of vancomycin resistance in the genus Streptococcus: characterization of a vanB transferable determinant in Streptococcus bovis. Antimicrob Agents Chemother 1997; 41: 24-29.
183. Sanders CC, Sanders WE, Jr. Enocin: an antibiotic produced by Streptococcus salivarius that may contribute to protection against infections due to group A streptococci. J Infect Dis 1982; 146: 683-690.
184. Dempster RP, Tagg JR. The production of bacteriocin-like substances by the oral bacterium Streptococcus salivarius. Arch Oral Biol 1982; 27: 151-7.
185. Ross KF, Ronson CW, Tagg JR. Isolation and characterization of the lantibiotic salivaricin A and its structural gene salA from Streptococcus salivarius 20P3. Appl Environ Microbiol 1993; 59: 2014-21.
186. Wescombe PA, Upton M, Dierksen KP, et al. Production of the lantibiotic salivaricin A and its variants by oral streptococci and use of a specific induction assay to detect their presence in human saliva. Appl Environ Microbiol 2006; 72: 1459-66.
187. Wescombe PA, Heng NC, Burton JP, Chilcott CN, Tagg JR. Streptococcal bacteriocins and the case for Streptococcus salivarius as model oral probiotics. Future Microbiol 2009; 4: 819-35.
188. Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res 2004; 119 Suppl: 13-16.
189. Eliopoulos GM. Current and new antimicrobial agents. Am Heart J 2004; 147: 587-92.
190. Manfredi R. [Therapeutic perspectives of linezolid in the management of infections due to multiresistant Gram-positive pathogens]. Recenti Prog Med 2007; 98: 143-54.
191. Nakamura S, Yanagihara K, Kaneko Y, et al. [A case of invasive group A Streptococcus infection which was successfully treated with linezolid]. Kansenshogaku Zasshi 2004; 78: 446-50.
192. Barry JS, Burge JA, Byles DB, Morgan MS. Severe invasive beta haemolytic group A streptococcal cellulitis and eyelid necrosis treated with linezolid. Br J Ophthalmol 2006; 90: 1204.
193. Sparo MD, Jones DG, Sanchez Bruni SF. Assessment of the in vitro efficacy of the novel antimicrobial peptide CECT7121 against human Gram-positive bacteria from serious infections refractory to treatment. Chemotherapy 2009; 55: 270-7.
194. Ho K. Bacteriophage therapy for bacterial infections. Rekindling a memory from the pre-antibiotics era. Perspect Biol Med 2001; 44: 1-16.
195. Thacker PD. Set a microbe to kill a microbe: drug resistance renews interest in phage therapy. JAMA 2003; 290: 3183-5.
196. Hagens S, Habel A, von Ahsen U, von Gabain A, Blasi U. Therapy of experimental pseudomonas infections with a nonreplicating genetically modified phage. Antimicrob Agents Chemother 2004; 48: 3817-22.
197. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol 1982; 128: 307-18.
198. Soothill JS. Bacteriophage prevents destruction of skin grafts by Pseudomonas aeruginosa. Burns 1994; 20: 209-11.
199. Biswas B, Adhya S, Washart P, et al. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycinresistant Enterococcus faecium. Infect Immun 2002; 70: 204-10.
200. Jado I, Lopez R, Garcia E, et al. Phage lytic enzymes as therapy for antibiotic-resistant Streptococcus pneumoniae infection in a murine sepsis model. J Antimicrob Chemother 2003; 52: 967-73.
201. Nelson D, Loomis L, Fischetti VA. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci USA 2001; 98: 4107-12.
202. Schuch R, Nelson D, Fischetti VA. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 2002; 418: 884-9.
203. Yoong P, Schuch R, Nelson D, Fischetti VA. Identification of a broadly active phage lytic enzyme with lethal activity against antibiotic-resistant Enterococcus faecalis and Enterococcus faecium. J Bacteriol 2004; 186: 4808-12.
204. Fischetti VA, Nelson D, Schuch R. Reinventing phage therapy: are the parts greater than the sum? Nat Biotechnol 2006; 24: 1508-11.
205. Cheng Q, Nelson D, Zhu S, Fischetti VA. Removal of group B streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme. Antimicrob Agents Chemother 2005; 49: 111-7.
206. Fischetti VA. Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol 2005; 13: 491-6.
207. Matsuzaki S, Rashel M, Uchiyama J, et al. Bacteriophage therapy: a revitalized therapy against bacterial infectious diseases. J Infect Chemother 2005; 11: 211-9.
208. Young R. Bacteriophage lysis: mechanism and regulation. Microbiol Rev 1992; 56: 430-81.
209. Loeffler JM, Fischetti VA. Synergistic lethal effect of a combination of phage lytic enzymes with different activities on penicillin-sensitive and -resistant Streptococcus pneumoniae strains. Antimicrob Agents Chemother 2003; 47: 375-7.
210. Pritchard DG, Dong S, Baker JR, Engler JA. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30. Microbiology 2004; 150: 2079-87.
211. Musser JM, DeLeo FR. Toward a genome-wide systems biology analysis of host-pathogen interactions in group A Streptococcus. Am J Pathol 2005; 167: 1461-72.
212. Zagursky RJ, Anderson AS. Application of genomics in bacterial vaccine discovery: a decade in review. Curr Opin Pharmacol 2008; 8: 632-8.
213. Rodriguez-Ortega MJ, Norais N, Bensi G, et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006; 24: 191-7.
214. Severin A, Nickbarg E, Wooters J, et al. Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 2007; 189: 1514-22.
215. Trevino J, Perez N, Ramirez-Pena E, et al. CovS simultaneously activates and inhibits the CovR-mediated repression of distinct subsets of group A Streptococcus virulence factor-encoding genes. Infect Immun 2009; 77: 3141-3149.
216. Churchward G. The two faces of Janus: virulence gene regulation by CovR/S in group A streptococci. Mol Microbiol 2007; 64: 34-41.
217. Shea PR, Beres SB, Flores AR, et al. Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proc Natl Acad Sci USA 2011; 108: 5039-44.
218. Shea PR, Virtaneva K, Kupko JJ, 3rd, et al. Interactome analysis of longitudinal pharyngeal infection of cynomolgus macaques by group A Streptococcus. Proc Natl Acad Sci USA 2010; 107: 4693-4698.